Zacks Investment Research upgraded shares of Beyondspring (NASDAQ:BYSI) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $23.00 target price on the stock.
According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “
Several other analysts have also recently weighed in on BYSI. Maxim Group restated a buy rating and set a $58.00 price objective on shares of Brinker International in a research report on Tuesday, April 30th. HC Wainwright restated a buy rating and set a $60.00 price objective on shares of Beyondspring in a research report on Wednesday.
Shares of NASDAQ:BYSI opened at $20.70 on Wednesday. The firm has a fifty day moving average price of $19.20. Beyondspring has a one year low of $13.06 and a one year high of $26.98.
Beyondspring (NASDAQ:BYSI) last posted its quarterly earnings data on Wednesday, July 10th. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.31. On average, equities research analysts anticipate that Beyondspring will post -1.15 earnings per share for the current year.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Story: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.